Agenus Inc AGEN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AGEN is a good fit for your portfolio.
News
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agenus Inc. - AGEN
-
Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agenus Inc. - AGEN
-
AGEN Investors Have Opportunity to Join Agenus Inc. Securities Fraud Investigation with the Schall Law Firm
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agenus Inc. - AGEN
-
AGEN Investors Have Opportunity to Join Agenus Inc. Securities Fraud Investigation with the Schall Law Firm
-
Agenus Shares Sink After FDA Discourages Accelerated Approval
-
Agenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal Cancer
Trading Information
- Previous Close Price
- $5.97
- Day Range
- $5.99–6.65
- 52-Week Range
- $4.78–32.00
- Bid/Ask
- $6.45 / $6.56
- Market Cap
- $137.76 Mil
- Volume/Avg
- 760,652 / 929,969
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.73
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body’s immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 389
- Website
- https://www.agenusbio.com
Comparables
Valuation
|
Metric
|
AGEN
|
ZYME
|
NTLA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 3.27 | — |
Price/Book Value | — | 1.73 | 2.46 |
Price/Sales | 0.73 | 15.16 | 44.05 |
Price/Cash Flow | — | — | — |
Price/Earnings
AGEN
ZYME
NTLA
Financial Strength
|
Metric
|
AGEN
|
ZYME
|
NTLA
|
|---|---|---|---|
Quick Ratio | 0.21 | 6.61 | 8.45 |
Current Ratio | 0.24 | 6.92 | 9.03 |
Interest Coverage | −1.26 | — | — |
Quick Ratio
AGEN
ZYME
NTLA
Profitability
|
Metric
|
AGEN
|
ZYME
|
NTLA
|
|---|---|---|---|
Return on Assets (Normalized) | −67.56% | −20.22% | −26.32% |
Return on Equity (Normalized) | — | −26.00% | −31.79% |
Return on Invested Capital (Normalized) | — | −28.86% | −32.85% |
Return on Assets
AGEN
ZYME
NTLA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Ykxfvzdxbv | Qrz | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Swvmthyl | Rzhzy | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Knrxpcmp | Xgvpwm | $118.7 Bil | |||
| Moderna Inc
MRNA
| Mfngsqgg | Dpwfl | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Jrqqxdpq | Xswpbx | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Bmzcqffg | Skp | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Ysdsmhgg | Vjg | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Bpjtxjsp | Rjxzzlm | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Zxkvpplyg | Bjg | $15.0 Bil | |||
| Incyte Corp
INCY
| Jnssfdvd | Ffzvyh | $13.5 Bil |